Search research articles
Contact Us
Filters
Showing results (411-420 of 416) with videos related to
Page
of 42
Sort By:
You have reached the last page of results.
This site can display upto 416 results.
Hepatology (Baltimore, Md.)
|
November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
Anna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Lancet (London, England)
|
October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C Parker, Nicholas D James, Christopher D Brawley, et al.
Research Square
|
February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
Marina A Parry, Emily Grist, Larissa Mendes, et al.
Nature Medicine
|
April 3, 2019
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
Mohsen Malehmir, Dominik Pfister, Suchira Gallage, et al.
International Journal of Cancer
|
April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)
Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Nature
|
February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Page
of 42
Search research articles
Search
Showing results (411-420 of 416) with videos related to
Sort By:
Page
of 42
You have reached the last page of results.
This site can display upto 416 results.
Hepatology (Baltimore, Md.)
|
November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
Anna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Lancet (London, England)
|
October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C Parker, Nicholas D James, Christopher D Brawley, et al.
Research Square
|
February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
Marina A Parry, Emily Grist, Larissa Mendes, et al.
Nature Medicine
|
April 3, 2019
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
Mohsen Malehmir, Dominik Pfister, Suchira Gallage, et al.
International Journal of Cancer
|
April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)
Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Nature
|
February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Page
of 42